Biogen Idec, Genentech submit Rituxan sBLAs for CLL

Biogen Idec Inc. (NASDAQ:BIIB) and Genentech Inc. submitted two sBLAs to FDA for Rituxan rituximab: one for the first-line treatment of chronic lymphocytic leukemia (CLL), the other for relapsed CLL. ...